The latest price target for Atara Biotherapeutics (NASDAQ:ATRA) was reported by Freedom Broker on May 18, 2026. The analyst firm set a price target for $10.00 expecting ATRA to rise to within 12 months (a possible 0.81% upside). 6 analyst firms have reported ratings in the last year.

The latest analyst rating for Atara Biotherapeutics (NASDAQ:ATRA) was provided by Freedom Broker, and Atara Biotherapeutics upgraded their hold rating.

The last upgrade for Atara Biotherapeutics Inc happened on May 18, 2026 when Freedom Broker raised their price target to $10. Freedom Broker previously had a sell for Atara Biotherapeutics Inc.

The last downgrade for Atara Biotherapeutics Inc happened on January 21, 2026 when Freedom Broker changed their price target from $16 to $4 for Atara Biotherapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Atara Biotherapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Atara Biotherapeutics was filed on May 18, 2026 so you should expect the next rating to be made available sometime around May 18, 2027.

While ratings are subjective and will change, the latest Atara Biotherapeutics (ATRA) rating was a upgraded with a price target of $4.00 to $10.00. The current price Atara Biotherapeutics (ATRA) is trading at is $9.92, which is within the analyst’s predicted range.